Merck & Co., Inc. is 20.0x more valuable than Jazz Pharmaceuticals plc by market capitalization ($294.13 B vs $14.73 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | JAZZ | MRK |
|---|---|---|
| Market cap | $14.73 B | $294.13 B |
| US-listed rank | #745 | #44 |
| Revenue (latest FY) | $4.27B | $65.01B |
| Net income (latest FY) | -$356.15M | $18.25B |
| Net margin | -8.3% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 2,093 | 996 |
Merck & Co., Inc. is 20.0x more valuable than Jazz Pharmaceuticals plc by market capitalization ($294.13 B vs $14.73 B).
In their latest fiscal years, Jazz Pharmaceuticals plc reported $4.27B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Jazz Pharmaceuticals plc and Merck & Co., Inc., or browse the full rankings.